https://www.selleckchem.com/pr....oducts/cobimetinib-g
injury burden. LEVEL OF EVIDENCE Prognostic, level III.BACKGROUND Patients with blunt cerebrovascular injuries (BCVI) are at risk of thromboembolic stroke. Although primary prevention with antithrombotic therapy is widely used in this setting, its effectiveness is not well defined, and requires further investigation. The aim of this study was to evaluate the utility of MRI-detected ischemic brain lesions as a possible future outcome for randomized clinical trials in this patient population. METHODS This prospective o
Like
Comment
Share
